Rhinosinusitis, Rhinosinusitis Acute, Sinus Infection, Sinusitis, Sinusitis, Acute
Conditions
Brief summary
The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.
Interventions
DRUGInfex 400 MR
Infex (cefpodoxime) 400mg once a day (QD) for 10 days
DRUGInfex 200 IR
Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
Sponsors
Neutec Ar-Ge San ve Tic A.Ş
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years and older patients who have acute bacterial rhinosinusitis sign and symptoms (i, ii, iii) according to IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults: i. Onset with persistent symptoms or signs\* compatible with acute rhinosinusitis, lasting for ≥ 10 days without any evidence of clinical improvement, ii. Onset with severe symptoms or signs of high fever \> 39 and purulent nasal discharge or facial pain lasting for at least 3-4 consecutive days at the beginning of illness, iii. Onset with worsening symptoms or signs characterized by the new onset of fever, headache, or increase in nasal discharge that lasted 5-6 days and were initially improving. (\*Major symptoms: Purulent anterior nasal discharge, Purulent or discolored posterior nasal discharge, Nasal congestion or obstruction, Facial congestion or fullness, Facial pain or pressure, d Hyposmia or anosmia. \*Minor symptoms: Headache, Ear pain, pressure, or fullness, Halitosis, Dental pain, Cough, Fatigue) 2. Patients who are able to give culture sample from middle meatus (microorganisms to be teste: Streptococcus pneumoniae, Haemophilus influenzae \[including beta-lactamase producing strains\], Streptococcus pyogenes and Moraxella catarrhalis \[including beta-lactamase producing strains\]). 3. Patients who are able to use oral drugs, 4. If patient is a women of childbearing age; female patients who applies appropriate birth control, 5. Patients who have ability to communicate with investigators, 6. Patients who commits to adhere to the study protocol, 7. Patients who sign informed consent form.
Exclusion criteria
1. Patients who have hypersensitivity to beta-lactam antibiotics, penicillin and cefpodoxime, 2. Patients who hypersensitivity to peanut and soy, 3. Patients who have kidney or liver deficiency, 4. Patients who have history of more than 2 bacterial sinusitis episode within last 12 months, 5. Patients who have chronic sinusitis, 6. Patients who have history of head and neck surgery and/or severe sinusitis complication (brain abscess or venous thrombosis), 7. Patients who are hospitalized within 4 weeks prior to the start of study, 8. Patients who have immunodeficiency (i.e; HIV, corticosteroid use, immunosuppressive use), 9. Patients who used antibiotics within 30 days prior to the start of study, 10. Patients who need to use of antibiotics other than investigational drugs for concomitant disease, 11. Patients who used aluminium and magnesium containing anti-acids, probenecid and iron containing drugs within 2 weeks prior to the start of study, 12. Pregnant and lactating female patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of formulations on acute sinusitis symptoms | 10 days | Change in acute sinusitis sign and symptoms at the end of treatment compared to baseline. The outcome will be assessed by Sino-nasal Outcome Tests SNOT-22 and SNOT-16. \* SNOT-16 is recommended symptom questionnarie for acute rhinonusitis but Turkish validation is not existed. Therefore SNOT-22 is also added as a symptom questionnarie since Turkish Validation is available. |
| Effect of formulations on quality of life scale | 10 days | Quality of Life: Increase or decrease in quality of life. The outcome will be assessed by Short Form Health Survey (SF-12). |
| Rate of microbiological response at the end of treatment | 10 days | Patients will be given sample from middle meatus. The outcome will be assessed according to microbiologic response: Eradication: The absence of pathogen(s) at the end of treatment. Persistance: The same concentration of the pathogen(s) in culture after the end of treatment. Superinfection: Detection of bacterial of fungal pathogens during or after treatment, |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the safety of investigational products | 10 days | Number of Adverse Events That Are Related to Treatments and Participants with Abnormal Laboratory Values (hemogram, sedimentation, CRP) |
Countries
Turkey (Türkiye)
Contacts
Primary ContactNeutec RDC
Outcome results
None listed